NCT00162448View on ClinicalTrials.gov

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2005

Conditions
Heart Diseases
Interventions
DRUG

BMS-394136

Oral Solution, Oral, 100 mg, Single dose, 1 day.

DRUG

Placebo

Oral Solution, Oral, 0 mg, Single dose, 1 day.

Trial Locations (3)

Unknown

Local Institution, Salisbury

Local Institution, Ann Arbor

Local Institution, Columbus

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY